Robert Stuart to Cost-Benefit Analysis
This is a "connection" page, showing publications Robert Stuart has written about Cost-Benefit Analysis.
Connection Strength
0.186
-
Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion. 2012 Nov; 52(11):2375-81.
Score: 0.084
-
Cost effectiveness of high-dose intravenous esomeprazole for peptic ulcer bleeding. Pharmacoeconomics. 2010; 28(3):217-30.
Score: 0.072
-
Electronic clinical trial protocol distribution via the World-Wide Web: a prototype for reducing costs and errors, improving accrual, and saving trees. J Am Med Inform Assoc. 1997 Jan-Feb; 4(1):25-35.
Score: 0.029